Tuesday, May 30, 2023


Biotechnology News Magazine

AR882 Phase 2B Study Enrollment Reported Completed

Latest Posts

Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

Airway Therapeutics began recruiting patients on March 28, 2023, for daily treatment up to 7 days at the highest dose of zelpultide alfa (rhSP-D) following a Data Safety Monitoring Committee (DSMC) report of no safety concerns.

Roche introduces navify® Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care

At the global HIMSS1 Conference, Roche showcases navify Algorithm Suite, a single platform offering clinicians access to medical algorithms generating insights to help improve care decisions.

PathO3Gen Solutions UVZone® Proven 99.9993% Effective Against Candida Auris: Shoes and Floors in Healthcare Facilities Should Be Addressed as Outbreak Continues

PathO3Gen Solutions’ multi-patented UVZone Shoe Sanitizing Stations, when placed in high-traffic and high-risk areas, enhance healthcare facility infection control measures, and may improve overall hospital biosafety.

Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.

Under the terms of Pharming's 2019 exclusive license agreement with Novartis for leniolisib, the corresponding first commercial sale of Joenja® triggers a $10 million milestone payment by Pharming to Novartis.

Arthrosi Therapeutics, Inc., a clinical-stage biotechnology company, today announced the completion of enrollment for its global Phase 2b clinical study of AR882 for the treatment of chronic gout. The study, which exceeded the initial target enrollment of 120 patients, is designed to evaluate the safety and efficacy of AR882, an effective and selective uricosuric agent, in chronic gout patients who meet ACR/EULAR gout classification.

“We are pleased to see the completion of enrollment in our global Phase 2b clinical study of our leading compound, AR882. The study has exceeded our initial enrollment target despite the COVID-19 pandemic. This is a major milestone for the development of AR882 for chronic gout treatment,” said Arthrosi CEO Litain Yeh.  “I thank the patients who enrolled in this study, the efforts of clinical investigators from the U.S., Australia, and Taiwan, and our clinical operations team who worked diligently to advance the study to this point. We look forward to providing a clinical update later this year.”

The Phase 2b randomized, double-blind, placebo-controlled, multicenter clinical study is designed to enroll approximately 120 gout patients to assess safety and efficacy of AR882 in three cohorts: 50 mg, 75 mg, or placebo. Study participants will receive treatment for up to three months to evaluate serum urate (sUA) reduction and safety. A total of 24 clinical sites have participated. As of August 15, 2022, 92 patients and 75 patients have passed the six-week and three-month dosing milestones respectively.

“AR882 has the potential to transform gout treatment. The data collected in our Phase 2a study has shown that AR882 is well-tolerated, with robust serum urate lowering effect in patients with gout,” said Arthrosi’s Chief Medical Officer Robert T. Keenan, MD, MPH, MBA. “We are confident the data will show similar efficacy, safety, and tolerability in this study, which is even larger and longer than the 2a study. The current standard of care has been ineffective in controlling rising rates of the disease and associated patient morbidity. AR882 was designed to treat patients with chronic gout to achieve serum urate levels below 6 mg/dL needed to control disease, and to achieve a target below 5 mg/dL or 4 mg/dL for more aggressive treatment.”

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine